AKT1 and neoplasm: Targeted therapy is designed to selectively inhibit molecular pathways dysregulated in GB cells without impairing normal cells, as for example Epidermal Growth Factor Receptor (EGFR), Platelet-Derived Growth Factor Receptor (PDGFR), Vascular Endothelial Growth Factor (VEGF) or Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (AKT)/Mechanistic Target of Rapamycin (mTOR), all critical for tumor progression [28,29].